【Principles of the Procedure】

The 2019-nCOV IgM Antibody Assay Reagent Kit (CMIA) is a two-step immunoassay using magnetic particle chemiluminescence technology. It can precisely determine the presence of anti-2019-nCOVIgM antibodies in human serum or plasma.

During the reaction, the first step is protein binding by mixing the sample with strong paramagnetic particles coated with the 2019-nCoV nuclear protein antigen. After washing, the alkaline phosphataselabeled murine anti-human IgM monoclonal antibody is added in the second step to form a magnetic particle-nucleoprotein_anti-2019-nCoV-IgM murine-anti-IgM-ALP-enzyme reaction mixture. After another wash cycle, the substrate of the alkaline phosphatase is added to the reaction mixture. The resulting chemiluminescence reaction is then measured in relative light units (RLU). The concentration of the anti-2019-nCoV -IgM antibody in the sample is proportional to the amount of relative light units (RLU) of the mixture. So the result can be used to detect the existence of the IgM in the sample and aid to determine if the patient has been infected by the 2019-nCoV virus.